Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:European_Medicines_Agency
gptkb:U._S._Food_and_Drug_Administration |
| gptkbp:atccode |
L02 BX03
|
| gptkbp:availability |
prescription only
|
| gptkbp:bioavailability |
100% (subcutaneous)
|
| gptkbp:chemical_formula |
C80 H104 N18 O16 S
|
| gptkbp:class |
hormonal therapy
|
| gptkbp:clinical_trial |
NCT00083045
NCT00104604 NCT00104610 NCT00104617 NCT00104630 |
| gptkbp:clinical_use |
used in hormone-sensitive prostate cancer
|
| gptkbp:contraindication |
hypersensitivity to degarelix
|
| gptkbp:dosage_form |
solution for injection
|
| gptkbp:duration |
as long as necessary
|
| gptkbp:effective_date |
gptkb:2008
|
| gptkbp:financial_support |
available through manufacturer programs
|
| gptkbp:formulation |
single-use prefilled syringe
|
| https://www.w3.org/2000/01/rdf-schema#label |
Firmagon
|
| gptkbp:indication |
advanced prostate cancer
|
| gptkbp:ingredients |
gptkb:degarelix
|
| gptkbp:interacts_with |
no significant drug interactions known
|
| gptkbp:invention |
patented
|
| gptkbp:is_monitored_by |
testosterone levels
|
| gptkbp:label |
contains black box warning for hypersensitivity
|
| gptkbp:lifespan |
approximately 30 days
|
| gptkbp:manufacturer |
gptkb:Ferring_Pharmaceuticals
|
| gptkbp:marketed_as |
many countries worldwide
|
| gptkbp:mechanism_of_action |
gonadotropin-releasing hormone antagonist
|
| gptkbp:name |
not on WHO Model List of Essential Medicines
|
| gptkbp:patient_education |
important for understanding treatment
|
| gptkbp:patient_population |
adult men
|
| gptkbp:pharmacokinetics |
reduces testosterone levels
rapid absorption after injection |
| gptkbp:previous_name |
no generic version available yet
|
| gptkbp:price |
varies by region and insurance
|
| gptkbp:provides_guidance_on |
included in prostate cancer treatment guidelines
|
| gptkbp:research |
ongoing studies for other cancers
|
| gptkbp:rounds |
hepatic and renal
|
| gptkbp:route_of_administration |
subcutaneous injection
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:service_frequency |
once a month
|
| gptkbp:side_effect |
fatigue
nausea weight gain injection site reactions hot flashes serious allergic reactions possible |
| gptkbp:storage |
refrigerated
|
| gptkbp:trade |
gptkb:Firmagon
|
| gptkbp:type_of_care |
important for treatment efficacy
|
| gptkbp:used_for |
gptkb:Oncology
|
| gptkbp:weight |
1730.0 g/mol
|
| gptkbp:bfsParent |
gptkb:Zoladex
|
| gptkbp:bfsLayer |
5
|